889858-12-2

Basic information

• Product Name: tert-Butyl 2-bromo-4-fluorobenzoate
• Synonyms: tert-Butyl 2-bromo-4-fluorobenzoate;2-Methylpropan-2-yl 4-bromo-2-fluorobenzoate;4-Bromo-2-fluoro-benzoic acid tert-butyl ester;Benzoic acid,4-bromo-2-fluoro-, 1,1-dimethylethyl ester;tera-butyl 4-Bromo-2-fluorobenzoate
• CAS NO: 889858-12-2
• Molecular Formula: C₁₁H₁₂BrFO₂
• Molecular Weight: 275.12
• Mol File: 889858-12-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 281ºC at 760 mmHg
• Flash Point: 123.7ºC
• Appearance: /
• Density: 1.394g/cm3
• Vapor Pressure: 0.00366mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-Butyl 2-bromo-4-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 2-bromo-4-fluorobenzoate(889858-12-2)
• EPA Substance Registry System: tert-Butyl 2-bromo-4-fluorobenzoate(889858-12-2)

Safety Data

• Hazardous Substances Data: 889858-12-2(Hazardous Substances Data)

Usage

General Description

Tert-Butyl 2-bromo-4-fluorobenzoate is a chemical compound generally used in scientific and chemical researches. It is an aromatic ester that includes a functional group, bromo-fluoro substituent. It's known for its clear colorless or light yellow appearance. This chemical is involved in different chemical reactions especially in organic synthesis where it serves as an essential intermediate. As with any chemical substance, proper handling and cautionary measures should be observed during its use to prevent any untoward incidents or reactions. Its exact properties such as melting point, boiling point, and solubility may vary and usually depend on multiple factors like temperature and pressure.

InChI:InChI=1/C11H12BrFO2/c1-11(2,3)15-10(14)8-5-4-7(13)6-9(8)12/h4-6H,1-3H3

Upstream product

• 151982-51-3 4-bromo-2-fluorobenzoyl chloride 
• 75-65-0 tert-butyl alcohol 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 115-11-7 isobutene 
• 24424-99-5 di-tert-butyl dicarbonate 
• 105931-73-5 1-bromo-3-fluoro-4-iodobenzene 
• 1435-52-5 2,5-dibromofluorobenzene 

Downstream Products

• 1628047-84-6 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-bromobenzoic acid tert-butyl ester 
• 1034974-86-1 N-[5-(3,5-difluoro-benzenesulfonyl)-1H-indazol-3-yl]-2-((R)-2-methoxy-1-methyl-ethylamino)-4-(4-methyl-piperazin-1-yl)-benzamide 
• 1351501-00-2 tert-butyl 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate 
• 1715032-88-4 4-(3-amino-6-((1R,3R,4R)-3-fluoro-4-hydroxycyclohexyl)pyrazin-2-yl)-2-fluorobenzoic acid 

Relevant articles and documents

TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS

Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X11 and X22 are independently C or N, provided that zero or one of X11 and X22 is N; Ring A represented by the structure is: or; and Q, R11, R22, R33, R44, R66, and p are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

Method for synthesizing key intermediate of venetoclax

The invention relates to the technical field of medicine synthesis, in particular to a method for synthesizing a key intermediate of venetoclax. The method comprises the following steps: with 4-bromo-2-fluorobenzoic acid (I) as a raw material, carrying ou

Development of a Convergent Large-Scale Synthesis for Venetoclax, a First-in-Class BCL-2 Selective Inhibitor

The process development of a new synthetic route leading to an efficient and robust synthetic process for venetoclax (1: the active pharmaceutical ingredient (API) in Venclexta) is described. The redesigned synthesis features a Buchwald-Hartwig amination to construct the core ester 23c in a convergent fashion by connecting two key building blocks (4c and 26), which is then followed by a uniquely effective saponification reaction of 23c using anhydrous hydroxide generated in situ to obtain 2. Finally, the coupling of the penultimate core acid 2 with sulfonamide 3 furnishes drug substance 1 with consistently high quality. The challenges and solutions for the key Pd-catalyzed C-N cross-coupling will also be discussed in detail. The improved synthesis overcomes many of the initial scale-up challenges and was accomplished in 46% overall yield from 3,3-dimethyldicyclohexanone (6), more than doubling the overall yield of the first generation route. The new process was successfully implemented for producing large quantities of 1 with >99% area purity.